Sarep­ta seeks to ex­pand Duchenne gene ther­a­py Ele­v­idys use to tod­dlers

Sarep­ta Ther­a­peu­tics is meet­ing with the FDA in June to dis­cuss ex­pand­ing the use of its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py to pa­tients younger than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER